This activity already occurred and is no longer available.
JNM (October 2012) The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131 I 3.0
JNM, October 2012, Volume 53, Number 10

JNM (October 2012) The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131 I 3.0

JNM, October 2012, Volume 53, Number 10

Member Fee: Free
Non-Member Fee: $15.00

Release Date: October 1, 2012
Expiration Date: October 31, 2015

California Scope: 1.0 Therapy (1)

Authors
Edward B. Silberstein1 (Chair), Abass Alavi2, Helena R. Balon3, Susan E.M. Clarke4, Chaitanya Divgi5, Michael J. Gelfand6, Stanley J. Goldsmith7, Hossein Jadvar8, Carol S. Marcus9, William H. Martin10, J. Anthony Parker11, Henry D. Royal12, Salil D. Sarkar13, Michael Stabin14, and Alan D. Waxman15

1UC Health University Hospital, Cincinnati, Ohio; 2Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; 3Beaumont Health System, Royal Oak, Michigan; 4Guy's Hospital, London, United Kingdom; 5Columbia University Medical Center, New York, New York; 6Cincinnati Children's Medical Center, Cincinnati, Ohio; 7New York-Presbyterian/Weill Cornell Medical Center, New York, New York; 8University of Southern California, Los Angeles, California; 9University of California at Los Angeles, Los Angeles, California; 10Vanderbilt University Medical Center, Nashville, Tennessee; 11Beth Israel Deaconess Medical Center, Boston, Massachusetts; 12Mallinckrodt Institute of Radiology, St. Louis, Missouri; 13Jacobi Medical Center, Bronx, New York; 14Vanderbilt University, Nashville, Tennessee; and 15Cedars-Sinai Medical Center, Los Angeles, California

Disclosure
In accordance with ACCME Revised Standards for Commercial Support and SNM Conflict-of-Interest Policy, the authors have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.

Target Audience
This article contains information of value to physicians, technologists, and medical personnel taking care of patients with benign and malignant thyroid disease who may benefit from 131I therapy.

Objectives
On successful completion of this activity, participants should be able to describe:

  1. The benefits and limitations of 131I therapy for patients with thyroid disease.
  2. The preparation of these patients and determination of the optimal administered activity.
  3. The regulatory issues and radiation precautions to be followed.

Continuing Education Credit Information

AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity. To receive CE credit, learners must achieve a score of 80% on the post-course assessment and complete the evaluation. Release date: October 1, 2012 Expiration date: October 31, 2015.

 

ACPE (Pharmacists)
The Society for Nuclear Medicine and Molecular Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been designated as knowledge-based CPE. The universal program number for this enduring material is 0210-0000-12-357-H04-P. Total available credit for pharmacists is 1.0 hours or 0.10 CEUs. Release Date: October 1, 2012. Expiration Date: October 31, 2015. To receive CE credit, learners must achieve a score of 80% on the post-course assessment and complete the evaluation.

VOICE (Technologists)
The SNMMI, through its Verification of Involvement in Continuing Education (VOICE) program, has approved this journal article for a maximum of 1.0 continuing education hours (CEHs). VOICE-approved credit is recognized by most licensure states and by the NMTCB and ARRT as Category A credit. In order to receive CE credit, you must first complete the activity content. When completed, take the post-test assessment.  You must obtain a score of 80% to receive the CE credit.  You will have no more than 3 attempts to successfully complete the post-test. Release Date: October 1, 2012. Expiration Date: October 31, 2015. California Scope: 1.0 Therapy (T).


Minimum system requirements

Supported Internet Browsers:
- Microsoft Internet Explorer (version 7 or higher)
- Google Chrome (latest version)
- Mozilla Firefox (latest version)
- Apple Safari (version 4 or higher)

Plug-in: Adobe Acrobat Reader (
http://get.adobe.com/reader/)

For questions please contact the Education Department at
Education@snmmi.org

© 2014 SNMMI. All rights reserved.    Policy on Privacy and Confidentiality: http://www.snmmi.org/index.cfm?PageID=926 


Type:     Internet Activity (Enduring Material)
3882 Registered Users